GSK Outperforms Industry on Strength in Key Drugs & Vaccines
https://www.zacks.com/stock/news/2243568/gsk-outperforms-industry-on-strength-in-key-drugs-vaccines?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2243568
Mar 20, 2024 - Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
0
Top Research Reports for Microsoft, Coca-Cola & Accenture
https://www.zacks.com/commentary/2241249/top-research-reports-for-microsoft-coca-cola-accenture?cid=CS-ZC-FT-research_daily-2241249
Mar 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Coca-Cola Company (KO) and Accenture plc (ACN).
0
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azn-s-new-acquisition-fda-updates-for-nvo-lly-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2241296
Mar 15, 2024 - AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
0
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab
https://www.zacks.com/stock/news/2240861/pfizer-pfe-gets-eu-nod-for-expanded-use-of-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240861
Mar 14, 2024 - Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
0
Pfizer (PFE) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2240265/pfizer-pfe-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2240265
Mar 13, 2024 - In the closing of the recent trading day, Pfizer (PFE) stood at $28.22, denoting a +0.75% change from the preceding trading day.
0
Have $2,000? 2 Magnificent Stocks Ready for a Bull Run
https://www.fool.com/investing/2024/03/10/have-2000-2-magnificent-stocks-ready-for-a-bull-ru/?source=iedfolrf0000001
Mar 10, 2024 - These stocks are trading down, but investors may be overlooking some important points.
0
These 3 Dividend Stocks Yield More Than 5% but Their Payout Ratios Are Over 100%. Are Dividend Cuts Coming?
https://www.fool.com/investing/2024/02/21/these-3-dividend-stocks-yield-more-than-5-but/?source=iedfolrf0000001
Feb 21, 2024 - Relying on payout ratio alone can sometimes give investors a misleading picture of just how safe a dividend payment is.
0
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
https://www.fool.com/investing/2024/02/17/is-it-too-late-to-buy-these-2-brilliant-passive-in/?source=iedfolrf0000001
Feb 17, 2024 - Patience will be rewarded with these stocks.
0
The Bull Market Left These 3 Stocks Behind, but They're Buys Right Now
https://www.fool.com/investing/2024/02/04/the-bull-market-left-these-3-stocks-behind-but-the/?source=iedfolrf0000001
Feb 04, 2024 - Sometimes, undervalued market laggards have what it takes to catch up over the long haul.
0
Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates
https://www.zacks.com/stock/news/2220214/pharma-stock-roundup-pfe-mrk-nvo-sny-s-q4-earnings-fda-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2220214
Feb 02, 2024 - Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.
0